Influence of additional risk factors on the antihypertensive efficacy of eprosartan and telmisartan in patients with essential hypertension
DOI:
https://doi.org/10.14739/2310-1237.2017.3.118311Keywords:
hypertension, cardiac remodeling, dyslipidemia, obesity, smoking, eprosartan, telmisartanAbstract
Objective. The aim of this study is to determine the effect of additional risk factors on blood pressure parameters, cardiovascular remodeling and the state of vegetative balance of the heart rhythm in patients with stage II essential hypertension (EH) under treatment with eprosartan and telmisartan.
Materials and methods. The study included 100 patients with stage II essential hypertension (EH), 1–2 degrees with a low and moderate risk of developing cardiovascular complications. The smoker's status was 30.0 %, hypercholesterolemia more than 5 mmol/l – 69.0 %, overweight and obesity – 82.0 % of patients with EH. By randomisation, half of the patients received eprosartan in a daily dose of 600 mg, the rest received telmisartan at a daily dose of 80 mg for 6 months. Before the start of treatment and after 6 months of therapy, all the patients were subjected to the evaluation of general physical examinations, calculation of body mass index, determination of serum TC level, ECG Holter monitoring with analysis of heart rate variability, ambulatory blood pressure monitoring, echocardiography and duplex pulsed wave dopplerography of extracranial and intracranial vessels. Two weeks before the study, the patients did not take any antihypertensive drugs.Results. In patients with EH with additional risk factors using of eprosartan for 6 months is accompanied by a significant decrease in "office" SBP by 30.0 %, DBP by 21.6 %, PBP by 41.4 % and avg. BP by 25.5 %, regression of myocardial hypertrophy and improvement of diastolic function of the left ventricle. Eprosartan demonstrated a high antihypertensive efficacy on the effect on SBP in patients with EH with the presence/absence of tobacco smoking. However, the effect of eprosartan on DBP was better in patients with EH who do not have the status of a smoker. All the patients with EH, regardless of the presence or absence of an elevated level of total cholesterol, reached the target level of SBP under the influence of eprosartan. The antihypertensive effect of eprosartan against SBP was independent of the presence/absence of obesity in patients with EH. Eprosartan resulted in a significant increase in the maximum linear velocity in the left internal carotid artery by 2.8 % and in the vertebrobasilar region by 24.3 %. The total power of the spectrum under the influence of treatment significantly increased by 14.3 %.
Antihypertensive therapy with telmisartan within half a year causes a significant decrease in "office" SBP by 24.8 %, DBP by 20.0 %, PBP by 31.8 %, avg. BP by 22.2 % In patients with EH who have/do not have the status of smoker and in all 100 % of patients with normal and elevated total cholesterol telmisartan was equally effective in achieving the target level of SBP. Obesity or its absence also did not significantly affect the effectiveness of antihypertensive therapy with telmisartan in patients with EH. Telmisartan, like eprosartan, causes regression of left ventricular hypertrophy. Telmisartan has a positive effect on carotid blood flow and does not affect the blood flow of the vertebrobasilar region. There were no changes in the parameters of the vegetative balance under the influence of telmisartan.Conclusion. In patients with EH with additional factors of cardiovascular risk using both eprosartan and telmisartan for half a year is accompanied by a significant decrease in blood pressure, regression of myocardial hypertrophy and improvement of diastolic function of the left ventricle, improvement of blood flow in the carotid region. In contrast to telmisartan, eprosartan increases the total power of the heart rate variability spectrum and does not affect the level of total cholesterol. The influence of telmisartan on the blood flow in the vertebrobasilar region is absent. Smoking, obesity, hypercholesterolemia do not reduce the antihypertensive efficacy of telmisartan and eprosartan against SBP and DBP. However, eprosartan is less effective in reducing DBP in patients with EH who smoke.
References
Kovalevskaya, N. A., Koziolova, N. A., Bushmakina, A. V., & Shatunova, I. M. (2012). Dinamika obratnogo remodelirovaniya serdca i sosudov u bol´nykh gipertonicheskoj bolezn´yu v zavisimosti ot vybora i taktiki naznacheniya antigipertenzivnoj terapii so starta [Dynamics of reverse remodeling of the heart and blood vessels in patients with hypertensive disease, depending on the choice and tactics of prescribing antihypertensive therapy from the start]. Sistemnye gipertenzii, 9(2), 5–10. [in Russian].
Kozlovskij, V. I., & Simanovich, A. V. (2014). Priverzhennost´ k terapii u pacientov s arterial´noj gipertenziej II stepeni: obzor literatury i sobstvennye dannye [Adherence to therapy in patients with arterial hypertension II degree: a review of lit. and own data)]. Vestnik Vitebskogo gosudarstvennogo medicinskogo universiteta, 13(2), 6–16. [in Russian].
Ripp, T. M., Mordovin, V. F., & Karpov, R. S. (2010). Narushenie processov cerebrovaskulyarnoj regulyacii i kognitivnoj funkcii u pacientov s arterial´noj gipertoniej, vozmozhnosti korrekcii antagonistom receptorov k angiotenzinu II [Impairment of cerebrovascular regulation and of cognitive function in hypertensive patients: A possibility for correction by angiotensin II receptor blocker]. Arterial´naya gipertenziya, 16(5), 504–510. [in Russian].
Khafizova, L. Sh., Khamidullaieva, H. A., Kurbanova, D. R., & Karimova, B. Sh. (2015). E´ffektivnost´ dvojnoj kombinirovannoj terapii u bol´nykh arterial´noj gipertenziej s vysokim kardiovaskulyarnym riskom [Efficiency of Double Combined Therapy in Hypertensive Patients with High Cardiovascular Risk]. Arterial´naya gipertenziya, 4, 58–64. [in Russian].
Aaslid, R., & Newell, D. (Eds.) (1992). Transcranial Doppler. New York: Raven Press.
Abraham, H. M., White, C. M., & White, W. B. (2014). The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. Drug Safety, 38(1), 33–54. doi: 10.1007/s40264-014-0239-7
Savoia, C., Burger, D., Nishigaki, N., Montezano, A., & Touyz, R. M. (2011). Angiotensin II and the vascular phenotype in hypertension. Expert Rev. Mol. Med., 13, 11. doi: 10.1017/S1462399411001815.
Willis, L. M., El-Remessy, A. B., Somanath, P. R., Deremer, D. L., & Fagan, S. C. (2011). Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clinical Science, 120(8), 307–319. doi: 10.1042/CS20100389
Arumugam, S., Sreedhar, R., Thandavarayan, R., Karuppagounder, V., Krishnamurthy, P., Suzuki, K., et al (2016). Angiotensin receptor blockers: Focus on cardiac and renal injury. Trends in Cardiovascular Medicine, 26(3), 221–228. doi: 10.1016/j.tcm.2015.06.004
Heusser, K., Vitkovsky, J., Schmieder, R., & Schobel, H. (2003). AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Autonomic Neuroscience, 107(1), 45–51. doi: http://dx.doi.org/10.1016/S1566-0702(03)00053-5
Borghi, C., Morbini, M., & Cicero, A. (2015). Combination therapy in the extended cardiovascular continuum. Journal of Cardiovascular Medicine, 16(5), 390–399. doi: 10.2459/JCM.0000000000000240
Brown, T., Gonzalez, J., & Monteleone, C. (2017). Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. J. Clin. Hypertens, 19(12), 1377–1382. doi: 10.1111/jch.13097
Lezcano, E. J., Iñigo, P., Larraga, A. M., Barranquero, C., Gimenez, I., & Osada, J. (2014). Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zücker rats. Diabetology & Metabolic Syndrome, 6(1), 10. doi: 10.1186/1758-5996-6-10.
Akioyamen, L., Levine, M., Sherifali, D., O'Reilly, D., Frankfurter, C., Pullenayegum, E., et al. (2016). Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension. Journal of the American Society of Hypertension, 10(1), 55–69.e1. doi: 10.1016/j.jash.2015.11.005.
Mesquita, E., Demarchi, A., Bitencourt, D., Machado, P., Badran, P., Almeida, & R., Jorge, A. (2016). Cardiovascular Continuum 25 years – The Evolution of an Etiopathophysiology Model. International Journal of Cardiovascular Sciences, 29(1), 56–64. doi: 10.5935/2359-4802.20160002
Chopra, H., Ramakrishnan, S., Pancholia, A., & Bansal, M. (2015). Cardiological Society of India. New Delhi: JP Medical Ltd.
Puram, N., Karande, V., Ramanand, J., Ramanand, S., Halasawadekar, N., & Bhosale, R. (2016). Comparison of efficacy of telmisartan with losartan in patients of essential hypertension with cognitive impairment. International Journal of Basic and Clinical Pharmacology, 5(3), 702–706. doi: 10.18203/2319-2003.ijbcp20161504
Rajagopalan, S., Bakris, G., Abraham, W., Pitt, B., & Brook, R. (2013). Complete Renin-Angiotensin-Aldosterone System (RAAS) Blockade in High-Risk Patients: Recent Insights From Renin Blockade Studies. Hypertension, 62(3), 444–449. doi: 10.1161/HYPERTENSIONAHA.113.01504
Düsing, R. (2016). Pharmacological interventions into the renin–angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering. Therapeutic Advances in Cardiovascular Disease, 10(3), 151–161. doi: 10.1177/1753944716644130.
De Backer, G., Petrella, R., Goudev, A., Radaideh, G., Rynkiewicz, A., & Pathak, A. (2013). Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation – The POWER Survey. International Journal of Hypertension, 2013, 165789. doi: 10.1155/2013/165789
Sare, G., Ghadami, A., Ankolekar, S., England, T., Hammonds, F., Adrian, M., et al. (2013). Effect of Telmisartan on Cerebral and Systemic Haemodynamics in Patients with Recent Ischaemic Stroke: A Randomised Controlled Trial. ISRN Stroke, 2013, 9. doi: 10.1155/2013/587954
Inoue, T., Morooka, T., Moroe, K., Ikeda, H., & Node, K. (2007). Effect of Telmisartan on Cholesterol Levels in Patients with Hypertension - Saga Telmisartan Aggressive Research (STAR). Hormone and Metabolic Research, 39(5), 372–376. doi: 10.1055/s-2007-976544
Karas, M., Lacourcière, Y., LeBlanc, A., Nadeau, R., Dubé, B., Florescu, M., et al. (2005). Effect of the renin–angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. Journal of Hypertension, 23(6), 1251–1260. doi: 10.1097/01.hjh.0000170389.69202.53
Deguchi, I., Furuya, D., Fukuoka, T., & Tanahashi, N. (2012). Effects of telmisartan on the cerebral circulation of hypertensive patients with chronic-stage stroke. Hypertension Research, 35(12), 1171–1175. doi: 10.1038/hr.2012.105
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., et al. (2012). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 33(13), 1635–1701. doi: 10.1093/eurheartj/ehs092
O’Brien, E., Parati, G., Stergiou, G., Asmar, R., Beilin, L., Bilo, G., et al. (2013). European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. Journal of Hypertension, 31(9), 1731–1768. doi: 10.1097/HJH.0b013e328363e964
Fu, P., & Feng, Y. (2016). Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease. Chinese Medical Journal, 129(1), 81–87. doi: 10.4103/0366-6999.172599.
Fisher, J. P., & Paton, J. F. (2012). The sympathetic nervous system and blood pressure in humans: implications for hypertension. Journal of Human Hypertension, 26(8), 463–475. doi: 10.1038/jhh.2011.66
Foulquier, S., Lartaud, I., & Dupuis, F. (2014). Impact of Short-Term Treatment with Telmisartan on Cerebral Arterial Remodeling in SHR. PLoS ONE, 9(10), e110766. doi: 10.1371/journal.pone.0110766
Goudev, A., Berrou, J., & Pathak, A. (2012). Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study. Vascular Health and Risk Management, 8, 563–568. doi: 10.2147/VHRM.S34834
(1996). Heart Rate Variability : Standards of Measurement, Physiological Interpretation, and Clinical Use. Task force of the European Society of cardiology and North American Society of Pacing and Electrophysiology. Circulation, 93(5), 1043–1065. doi: https://doi.org/10.1161/01.CIR.93.5.1043
Kamo, T., Akazawa, H., & Komuro, I. (2015). Pleiotropic Effects of Angiotensin II Receptor Signaling in Cardiovascular Homeostasis and Aging. International Heart Journal, 56(3), 249–254. doi: 10.1536/ihj.14-429
Kim, S., Park, J., & O''Rourke, M. (2015). Vasculopathy of Aging and the Revised Cardiovascular Continuum. Pulse, 3(2), 141–147. doi: 10.1159/000435901
Must, A., Dallal, G. E., & Dietz, W. H. (1991). Must A. Reference data for obesity: 85th and 95th percentiles of body mass index (wt/ht2) and triceps skinfold thickness. Am. J. Clin. Nutr, 53(4), 839–846.
Mahmoudpour, S., Leusink, M., Putten, L., Terreehorst, I., Asselbergs, F., de Boer, A., & Maitland-van der Zee, A. (2013). Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics, 14(3), 249–260. doi: 10.2217/pgs.12.206
Pokharel, P., & Bella, J. (2013). Regression of left ventricular hypertrophy: Lessons from clinical trials. OA Evidence-Based Medicine, 1(2), 13.
Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., et al. (2011). Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. The Lancet Neurology, 10(1), 43–53. doi: 10.1016/S1474-4422(10)70250-7.
Kirchhof, P., Sipido, K., Cowie, M., Eschenhagen, T., Fox, K., Katus, H., et al. (2014). The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. European Heart Journal, 35(46), 3250–3257. doi: 10.1093/eurheartj/ehu312
Weber, M. (2003). The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme. Journal of Hypertension, 21(6), S37–S46. doi: 10.1097/00004872-200307006-00007
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
